매사추세츠의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 26개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06465069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06586957Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05422794A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT05983432A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT07513311First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07182149Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT07341867A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06176261Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 ~ 100세 · 모든 성별 · 2026. 7. 29. 업데이트됨 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT06150664Sacituzumab Govitecan In TNBC
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- Massachusetts General Hospital - North Shore Cancer Center, Danvers
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 17. 업데이트됨 · NCT04230109Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT07137416A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 23. 업데이트됨 · NCT07046923Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 4. 업데이트됨 · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Dana Farber Cancer Institute, Boston
- DFCI @ Foxborough, Foxborough
- DFCI @ Milford Regional Hospital, Milford
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 29. 업데이트됨 · NCT04468061This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 2. 업데이트됨 · NCT06451497A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06908928Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2024. 11. 15. 업데이트됨 · NCT04787042ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.